Molecular and clinical effects of selective TYK2 inhibition with deucravacitinib in psoriasis
收藏NIAID Data Ecosystem2026-03-13 收录
官方服务：
资源简介：
Investigate changes in IL-23/Th17- and type I interferon-pathway biomarkers and gene responses, and measures of selectivity for TYK2 over Janus kinases (JAKs) 1–3, in patients with moderate to severe psoriasis receiving deucravacitinib.EGA study EGAS00001005875
创建时间：
2021-12-17
